Year: 2014
Smokers group challenges NYC e-cigarette ban
A smokers' rights group filed a legal challenge on Tuesday to New York City's ban on electronic cigarettes in restaurants, parks and many other public places. The city has increasingly restricted places where regular cigarettes can be smoked over the last decade under the Smoke-Free Air Act. The group behind the lawsuit, New York City Citizens Lobbying Against Smoker Harassment, said the new legislation was in breach of the "one-subject rule" in both the state constitution and the city charter. The stated purpose of the Smoke-Free Air Act is to reduce New Yorkers' exposure to other people's cigarette smoke, the lawsuit says.
Medical marijuana pills or spray may ease multiple sclerosis pain
Can Exercise and an Occasional Drink Boost Eye Health?
Maker of Four Loko flavored malt liquor accepts marketing limits
The maker of Four Loko has agreed with 20 U.S. state attorneys general and the city of San Francisco to a series of reforms to resolve allegations that it improperly marketed flavored malt beverages to young people and encouraged alcohol abuse. Phusion Projects LLC, which is based in Chicago, agreed not to sell caffeinated alcoholic drinks, agreed not to promote binge drinking or other misuses of alcohol, and accepted marketing limits designed to keep people under 21 from buying alcoholic products. Among these limits are a ban on promoting flavored malt beverages on school or college property except at licensed retailers, and not using models or actors under age 25 or who appear to be under age 21 in its advertising. The danger of mixing caffeine and alcohol was spotlighted in 2010 when some college students were hospitalized for alcohol poisoning after drinking alcoholic energy drinks.
Dips ~ Most Valuable Exercise You're Not Doing – Iron Magazine
Among all popular diets, study says 'real food' is best
High court seems divided over birth control rule
March Into Your Weight–Loss Goals
(MKTW) African Gold Group, Inc. Announces Early Warrant Exercise Incentive Program
Pfizer lung cancer drug beats chemo for previously untreated patients
(Reuters) – Pfizer Inc's Xalkori delayed progression of lung cancer longer than chemotherapy in patients who had never previously been treated for the disease, according to results of a late-stage study released on Tuesday. The medicine, which received U.S. approval in 2011 for lung cancer patients who have a specific gene mutation, had shown in a previous Phase III trial that it significantly delayed disease progression among those who have already undergone chemotherapy for non-small-cell lung cancer, the most common form of the illness. Pfizer said favorable results from the latest trial, combined with those from the earlier big study, establish that Xalkori is appropriate for first-line as well as second-line use, meaning for patients receiving initial treatment as well as for those who have already undergone chemotherapy. The mutation only occurs in a small percentage of patients with lung cancer, but makes them good candidates for treatment with Xalkori.
Ray-Ban maker Luxottica to bring Google Glass to wider market
By Stephen Jewkes MILAN (Reuters) – Google has teamed up with Ray-Ban maker Luxottica in a bid to turn its Internet-connected Glass spectacles into a widely-available, stylish consumer product. In a statement late on Monday, Luxottica, the world's biggest eyewear maker, said it had agreed to design, develop and distribute Glass eyewear, which so far has only been available as an expensive prototype in the United States. Google Glass is a small stamp-sized screen attached to a pair of spectacle frames. The deal will allow Italy's Luxottica to be first to showcase the new technology to millions of potential consumers, although Google has yet to surmount challenges such as battery life and privacy concerns.